BioElectronics Corporation announced that it filed with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch(R) Therapy products. In this application the company will seek over-the-counter clearance of its ActiPatch Therapy products for the indication of general pain relief relative for general musculoskeletal complaints. The company intends to place the ActiPatch Therapy products for heel/foot, back, knee, wrist, and elbow pain on store shelves in the U.S. drug and grocery store channel upon FDA clearance. FDA clearance will also significantly enhance the marketability of the Company's products on a worldwide basis. The management team believes these markets are worth hundreds of millions of dollars per year. With very few products targeting these conditions having undergone the rigorous clinical trial and FDA clearance processes, BioElectronics believes its products will be highly differentiated relative to competing therapies.

BioElectronics Corp. announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP. Data on heel and foot pain shows strong efficacy and 100% safety using the ActiPatch(R) Therapy device. Results for pain reduction are significant as are the data indicating study participants were able to meaningfully reduce their use of pain medication. Study indicates that ActiPatch's effectiveness, ease-of-use and low cost make it a viable option for the tens of millions of people who suffer from heel and foot pain, including plantar fasciitis. Heel and foot pain, and plantar fasciitis are common conditions affecting tens of millions of people all over the world. It has been reported that plantar fasciitis occurs in 2 million Americans a year and 10% of the population over a lifetime. It is commonly associated with long periods of work related weight-bearing, and is especially prevalent in non-athletic populations with a high body mass index.

To discuss the results of a clinical study and provide an update on corporate activities and information on the status of FDA filings